Erythropoietin, a member of the type 1 cytokine superfamily, controls proliferation and differentiation of erythroid progenitor cells through binding to and dimerization of the erythropoietin receptor. Both erythropoietin and its receptor are also expressed in the central nervous system, where they are involved in tissue protection. However, the use of erythropoietin as a neuroprotective agent may be hampered by its erythropoietic activity. Therefore, developing non-haematopoietic erythropoietin mimetics is important. Based on the crystal structure of the complex of erythropoietin and its receptor, we designed a peptide, termed Epotris, corresponding to the C a-helix region (amino-acid residues 92-111) of human erythropoietin. The peptide specifically bound to the erythropoietin receptor and promoted neurite outgrowth and survival of primary neurons with the same efficiency as erythropoietin, but with 10 3 -fold lower potency. Knockdown of the erythropoietin receptor or interference with its downstream signalling inhibited the Epotris-induced neuritogenic and pro-survival effect. Similarly to erythropoietin, Epotris penetrated the blood-brain barrier. Moreover, treatment with the peptide attenuated seizures, decreased mortality and reduced neurodegeneration in an in vivo model of kainic acid-induced neurotoxicity. In contrast to erythropoietin, Epotris did not stimulate erythropoiesis upon chronic administration. Thus, Epotris is a novel neuroprotective non-haematopoietic erythropoietin mimetic that may offer new opportunities for the treatment of neurological disorders.
Introduction
Erythropoietin (EPO) is a pleiotropic cytokine that was initially identified as a regulator of red blood cell production in response to hypoxia. The mature human 165 amino acid-long EPO protein consists of four -helices, A-D, forming a compact globular structure. EPO induces haematopoiesis by dimerizing EPO receptor molecules, which leads to the activation of the EPO receptor-associated Janus tyrosine kinase 2 (Jak2) and secondary signalling molecules such as Stat5 (Brines and Cerami, 2005) . Recombinant EPO is widely used for the treatment of anaemia of various origins (Deechongkit et al., 2006) .
EPO also displays tissue protection properties. In the central nervous system, EPO and EPO receptor are expressed by neurons, glial cells and cerebrovascular endothelium (reviewed in Marti, 2004) . EPO was shown to be neurotrophic and neuroprotective in vitro and in animal models of neuronal injury associated with trauma, stroke, ischaemia, inflammation and epileptic seizures (Mammis et al., 2009) . The beneficial effects of EPO were also demonstrated in clinical studies of stroke, schizophrenia and progressive multiple sclerosis (Siren et al., 2009) .
EPO protects neurons both directly, by preventing apoptosis, and indirectly, by modulating inflammatory processes and stimulating neurogenesis and angiogenesis (Villa et al., 2003; Wang et al., 2004) . Although EPO is accepted as a safe therapeutic for treating anaemia, the clinical use of EPO as a cytoprotective drug raises concerns of its possible adverse side effects, such as thromboembolism, hypertension and tumour progression in patients with cancer (Henke et al., 2003; Rosenzweig et al., 2004; Bohlius et al., 2006) . The neuroprotective doses of peripherally administered EPO are much higher than those needed for stimulation of haematopoiesis (Brines and Cerami, 2005) . Therefore, the development of tissue-protective EPO analogues lacking erythropoietic activity is needed.
Several strategies have been used to identify neuroprotective non-haematopoietic EPO derivates. One of these derivates results from the removal of sialic acid from EPO. AsialoEPO displays neuroprotective activities without stimulation of haematopoiesis (Erbayraktar et al., 2003) . Another approach is carbamylation of EPO, which strongly reduces the binding affinity of EPO for EPO receptor. Carbamylated EPO is neuroprotective and does not stimulate haematopoiesis (Leist et al., 2004) . Carbamylated EPO was recently suggested to exert neuroprotection acting via a heteroreceptor complex formed by EPO receptor and the beta common receptor (bc, CD131; Brines et al., 2004) . Moreover, two peptides modelled after EPO helix B (HBP and HBSP), which is not involved in EPO receptor binding, were shown to have neuroprotective, but not erythropoietic, effects (Brines et al., 2008) .
The present study shows that a peptide encompassing the helix C motif of EPO, termed Epotris, binds to EPO receptor and induces neurite outgrowth and neuronal survival. We also demonstrate that systemically injected Epotris does not induce erythropoiesis. Epotris crosses the blood-brain barrier and has anticonvulsive and neuroprotective effects in a mouse model of kainic acid-induced neurotoxicity.
Material and methods

Peptides
Peptides were synthesized as monomers, dimers or tetramers (480% purity, Schafer-N, Copenhagen, Denmark). Dimers and tetramers consisted of two and four chains, respectively, coupled to a lysine backbone (see Supplementary Fig. 1 for the peptide composition). For determination of the peptide concentration in plasma, the tetrameric Epotris peptide (molecular weight = 9114.9) was N-terminally labelled with biotin (Schafer-N). Truncated and alanine-substituted versions of Epotris, including Epotris-N8 (molecular weight = 5550.7) were tested in tetrameric form.
Surface plasmon resonance analysis
Real-time surface plasmon resonance analysis was performed using a BIAcore 2000 instrument (Pharmacia Biosensor AB, Uppsala, Sweden). In total, 3900 resonance units of the Epotris peptide were noncovalently immobilized on a CM5 sensor chip (Pharmacia Biosensor AB). Binding of the extracellular domain of a human EPO receptor/ Fc chimera (45 nM, R&D Systems, Minneapolis, USA) was measured at 25 C in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-buffered saline (Pharmacia Biosensor AB) at a flow rate of 20 ml/min. After each binding cycle, the sensor chip was regenerated by one 5-ml injection of 25 mM acetic acid. Three independent experiments were performed. Alternatively, 500-1200 resonance units of the human or mouse EPO receptor or CD131 were immobilized covalently on a CM4 sensor chip (Pharmacia Biosensor AB) by amine coupling. Serial dilutions of Epotris or its derivates were injected in duplicate at a flow rate of 20 ml/min. Two independent experiments were performed. The recombinant human EPO (R&D Systems) was used as a positive control. Data were analysed using BIA evaluation software version 4.1 (Pharmacia Biosensor AB). Models of single-site binding association and dissociation were used to derive the apparent rate constants and K D .
Circular dichroism spectroscopy
A circular dichroism spectrum was recorded on a Jasco J-810 spectrapolarimeter using 15 mM peptide samples dissolved in 10 mM phosphate buffer at 20 C. The spectrum of the monomer was recorded at pH 6.6, and the spectra of the dimer and tetramer were recorded at pH 6.8. A 1 mm cuvette was used, and the slit width was set to 1 nm. Each spectrum was recorded from 250 nm to 190 nm as an average of five scans at a recording speed of 100 nm/min.
Hydrophobic cluster analysis
Hydrophobic cluster analysis allows the detection by a 2D transposition of the sequence (the hydrophobic cluster analysis plot) of the local hydrophobic compactness (hydrophobic clusters) associated with internal faces of regular secondary structures such as -helices and b-strands. Hydrophobic cluster analysis of the Epotris sequence was performed using Mobyle RPBC (http://mobyle.rpbs.univ-paris-diderot .fr/cgi-bin/portal.py?form=HCA).
Analysis of neurite outgrowth
Cerebellar granule neurons were isolated from 7-day-old Wistar rats, seeded at a density of 10 4 cells/cm 2 in uncoated eight-well LabTek Permanox slides (Nunc, Roskilde, Denmark) as previously described (Neiiendam et al., 2004) and incubated with peptides of interest for 24 h. Anti-EPO receptor or control IgG (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA), or AG490 (Calbiochem, La Jolla, CA, USA) were applied 1 h before the addition of peptides. For the co-culture assay, cerebellar granule neurons were seeded on top of confluent monolayers of mouse fibroblastoid L929 cells (L-cells, cultured as described in Hansen et al., 2007) and incubated for 24 h with either Epotris or recombinant human EPO. Cultures were immunostained for growth associated protein-43 as previously described (Soroka et al., 2002) . Evaluation of neurite outgrowth was performed as previously described (Ronn et al., 2000) . Primary hippocampal neurons were isolated from embryonic Day 19 Wistar rat embryos and cultured as described in Maar et al. (1997) . Because glial cells constitute a minor part of the total cell number in this culture type (Kiryushko et al., 2006) , Coomassie staining was employed to assess neurite outgrowth as previously described (Soroka et al., 2002) . To knock-down EPO receptor expression, 5 Â 10 6 neurons were transfected with 1 mg plasmid DNA encoding short-hairpin RNA for rat EPO receptor or control short-hairpin RNA (Santa Cruz Biotechnology) by electroporation using a nucleofector device and a Rat Neuron Nucleofector Kit (Amaxa, Gaithersburg, MD, USA). A pEGFP-N1 plasmid encoding the enhanced variant of green fluorescent protein (0.6 mg; Clontech Laboratories, Mountain View, CA, USA) was added as a transfection control. Immediately after transfection, neurons were seeded on top of L-cells and treated with EPO (5 nM) or Epotris (0.3 mM) for 24 h. Alternatively, transfected cells were seeded on poly-L-lysine-coated four-well slides (Nunc) and stimulated with Epotris for 24 h. Neurons were fixed and stained with mouse anti-green fluorescent protein antibody (Roche, Basel, Switzerland) to visualize transfected cells.
Analysis of neuronal survival Potassium withdrawal assay
To test the effects of Epotris on neuronal survival, long-term cerebellar granule neuron cultures were grown in Neurobasal-A medium containing 40 mM KCl as previously described (Neiiendam et al., 2004) . After 7 days, the cells were washed in Basal modified Eagle's medium (Gibco BRL, Paisly, UK) supplemented as described in Neiiendam et al. (2004) and containing only 5 mM KCl for the induction of apoptosis and stimulated with Epotris, recombinant human EPO (1.3 nM, Calbiochem, Seoul, South Korea) or recombinant human insulin-like growth factor 1 (6.6 nM, Gibco BRL) for 48 h. The cells were fixed in 4% v/v formaldehyde and stained with 5 mg/ml Hoechst 33258 (Invitrogen, Copenhagen, Denmark) or 5 mg/ml propidium iodide (Sigma). At least 1000 cells/condition were recorded in a systematic series of view fields, with the position of the first field chosen randomly as described in Ronn et al. (2000) . Cell viability was estimated based on nuclear morphology (dead cells displaying condensed chromatin or fragmented nuclei) in a semi-automatic mode using software developed at the laboratory to minimize bias. Results are presented as the mean of the live cell ratio [n live cells/(n live cells + n dead cells) AE SEM].
Kainic acid-induced cytotoxicity
Hippocampal neurons were plated at a density of 5 Â 10 4 cells per well in poly-L-lysine-coated eight-well LabTek Permanox slides (Nunc) as previously described (Soroka et al., 2002) . After 7 days in culture, neurons were treated with EPO (3 nM) or Epotris (0.001-3 mM) for 1 h followed by the addition of 300 mM freshly reconstituted kainic acid (Sigma, Brøndby, Denmark). Cells were further cultured for 24 h, fixed, stained and analysed as described for the potassium withdrawal assay.
Immunoblotting
Cerebellar granule neurons were seeded in 60 mm tissue culture dishes ($10 7 cells/dish) and grown for 4 h before treatment with vehicle, EPO (5 or 15 nM, Calbiochem) or Epotris (0.1-3 mM) for 10 min.
Immunoblotting was performed as previously described (Kolkova et al., 2000) using polyclonal goat anti-phosphoStat5 (1:1000, Santa Cruz Biotechnology) or polyclonal rabbit anti-b-actin (1:1000, Sigma).
To detect biotinylated Epotris, horseradish peroxidase-conjugated streptavidin (1:2000, DAKO, Glostrup, Denmark) was used. Protein bands were visualized and processed as described in Kiryushko et al. (2006) .
In vitro proliferation assay
Human myelo-erythroid leukaemia TF1 cells were cultured similarly to L-cells (see above) with the addition of 2 ng/ml granulocytemacrophage colony stimulating factor (Sigma). Cells were washed with granulocyte-macrophage colony stimulating factor-deprived medium, plated in 96-well microwell plates (Nunc; 5 Â 10 3 cells/well), and treated with Epotris (0-5.4 mM). As a positive control, 50 pM EPO was used. After 24 h of culture, cells were labelled with BrdU (final concentration 10 mM) for 24 h, centrifuged (300g, 10 min) and fixed. BrdU incorporation was detected using the Biotrak cell proliferation ELISA kit (GE Healthcare, Hillerød, Denmark) according to manufacturer's instructions.
Animal experiments
All animal experiments were performed according to European Union legislation with licenses from the Danish Animal Experiments Inspectorate. BALB/c and C57BL/6J mice were obtained from Taconic (Ejby, Denmark), and Wistar rats were obtained from either Taconic or Charles River (Sulzfeld, Germany).
Detection of Epotris in plasma and cerebrospinal fluid
Blood samples were collected from the orbital plexus of anaesthetized 200 g Wistar rats at 15 min, 30 min, 1, 2, 4, 8 and 24 h after single subcutaneous Epotris administration (10 mg/kg) as described in Secher et al. (2006) . Cerebrospinal fluid was sampled from the cisterna magna at 2 h, as previously described (Secher et al., 2006) . Epotris concentrations in plasma samples were measured using a competitive enzyme-linked immunosorbent assay. Ninety-six-well Amino TM plates (Nunc) were coated with 30 mg/ml biotinylated albumin (Sigma-Aldrich) diluted in 100 mM carbonate buffer (pH 9.6).
Plates were incubated for 2 h and washed three times with 0.05% v/v Tween 20 in phosphate buffered saline (PBST). One sample volume was mixed with three volumes of peroxidase-labelled streptavidin diluted 1:5000 in PBST and incubated for 30 min.
A quantity of 100 ml/well of the mixture was then added to biotinylated albumin-coated plates. Plates were incubated for 1 h, washed three times with PBST and developed with TMB plus (Kem-En-Tec, Taastrup, Denmark). The enzymatic reaction was stopped with 0.2 M sulphuric acid. Optical density was recorded at 450 nm using a Sunrise absorbance reader (Tecan, Mä nnedorf, Switzerland). All samples were run in duplicate.
Haematopoietic activity of Epotris
Female C57BL/6J mice, $25 g, received subcutaneous injections of Epotris (10, 20 or 40 mg/kg, n = 10/group), EPO (10 mg/kg, Calbiochem, n = 8) or vehicle (n = 8) twice per week for 5 weeks. Alternatively, female BALB/c mice received subcutaneous injections of Epotris (10 mg/kg, n = 10) or vehicle according to the aforementioned regimens. For control, EPO (34 mg/kg) was injected for 3 weeks. Blood samples were collected from the orbital plexus once per week in EDTA-coated tubes, and haemoglobin levels and red blood cell concentrations were determined using an automated analyser (KX-21N, Sysmex, Mundelein, IL, USA) with adapted dilutions. Haematocrit values were measured by microcapillary centrifugation.
To detect anti-Epotris antibodies in plasma, 96-well Amino TM plates
were coated with 30 mg/ml peptide in 100 mM carbonate buffer (pH 9.6) for 2 h. Plates were washed three times with PBST, and 20Â diluted plasma samples collected at Week 6 from vehicle-or peptide-treated mice were added. Plates were incubated for 1 h, washed three times with PBST, and incubated for 1 h with Envision Dual Link System Peroxidase (100 ml; Dako). Plates were further processed and developed as described for the competitive enzyme-linked immunosorbent assay (see above).
Kainic acid-induced seizures
Male C57BL/6J mice, 28-32 g, were injected subcutaneously with Epotris (10 mg/kg), EPO (50 mg/kg) or vehicle 48, 24 and 2 h prior to kainic acid treatment. Based on preliminary dose-adjustment experiments, two doses of kainic acid (intraperitoneal) were chosen to perform two sets of experiments to induce either low-grade seizures (20 mg/kg kainic acid) or high-grade seizures and mortality (30 mg/ kg kainic acid). Measured parameters included latency of seizure onset, seizure severity and mortality. Seizure activity was recorded for 2 h following kainic acid administration by an observer blind to treatment and assessed according to a modified Racine scale (0 = immobility; 1 = facial automatism; 2 = head nodding; 3 = forelimb clonus; 4 = rearing; 5 = generalized convulsions; 6 = death; Racine, 1972) . Seizure grades 1-3 were regarded as low-grade seizures, and seizure grades 4-5 were regarded as high-grade seizures. The latency of immobility was measured as the time between kainic acid injection and the appearance of immobility. The control group of animals received a vehicle injection.
Histology
Neurodegeneration induced by 20 mg/kg kainic acid was assessed at 24 h using haematoxylin-eosin staining (described in Sonn et al., 2010) or Fluoro-Jade C staining (described in McCord et al., 2008) . For haematoxylin-eosin staining, every 10th section through the hippocampus at a level corresponding to $1.3-2.8 mm posterior to bregma was taken. 
Results
The tetrameric form of Epotris, a peptide derived from the a-C helix of EPO, acquires helical conformation in solution EPO has a four-helical bundle topology (-helices A-D, Syed et al., 1998) . According to the crystal structure of the EPO-EPO receptor complex, one EPO molecule interacts with two receptor molecules via two binding sites located on opposite faces of the EPO protein (Syed et al., 1998) . These two receptor binding sites have been identified as Site 1 (K D $1 nM) and Site 2 (K D $1 mM), respectively. EPO residues belonging to Site 2 are located in helices A and C. In the C helix, the six residues Lys97, Ser100, Arg103, Ser104, Thr107 and Leu108 are the major contributors to the Site 2 binding interface (Syed et al., 1998 ; Protein Data Bank ID: 1EER). We designed a peptide, termed Epotris, encompassing 20 amino acid residues located in helix C and in the loop between helix C and the mini-helix C' of human EPO (92QLHVDKAVSGLRSLTTLLRA111; Protein Data Bank ID: 1EER) representing the second binding site of EPO (Fig. 1A and Supplementary Fig. 2A ). Simulation of the secondary structure of the Epotris peptide using NNPREDICT software (Kneller et al., 1990) showed that the peptide should contain an -helical core. When a segment consisting of 94HVDKAVSGLRSL105 is displayed on a helical wheel, an amphipathic helix enriched in hydrophobic side chains on one of its sides and enriched in hydrophilic side chains on the other side is clearly revealed (Supplementary Fig. 2B ). Hydrophobic cluster analysis (Callebaut et al., 1997) of Epotris also showed that hydrophobic and positively charged amino acids are not distributed randomly but rather form separate clusters, indicating an amphipathic helix (Supplementary Fig. 2C and D).
The Epotris peptide was synthesized as a monomer, dimer and tetramer (see 'Material and methods' section). Far-ultraviolet circular dichroism spectra of these three forms of Epotris showed double minima at 208 and 222 nm only for the tetrameric peptide, indicating that it forms an -helical structure in aqueous solution ( Supplementary Fig. 3) . Interestingly, the far-ultraviolet circular dichroism spectrum of Epotris was similar to that of recombinant EPO (Davis et al., 1987) , which was characterized by a negative minimum at 208 nm and a shoulder around 217 nm, with the calculated -helix content $50%. Thus, tetrameric Epotris acquired a conformation similar to -helix C of EPO. Therefore, this form of the peptide was used for all further experiments, unless otherwise indicated.
Epotris binds to the EPO receptor
We first tested whether the Epotris peptide interacted with EPO receptor by surface plasmon resonance analysis. Epotris, but not its scrambled version, dose-dependently bound to the immobilized EPO receptor (Fig. 1B) , indicating a sequence-specific interaction between Epotris and EPO receptor. To determine the binding affinity of this interaction, Epotris was immobilized on a sensor chip and EPO receptor was added as a soluble ligand. The K D value of Epotris:EPO receptor binding was 4.5 AE 2.5 nM ( Supplementary Fig. 4A ). Monomeric Epotris at concentrations equimolar to the tetramer did not interact with EPO receptor (Supplementary Fig. 4C ). In another surface plasmon resonance experiment (Fig. 1C) , the affinity of EPO binding to the immobilized EPO receptor was determined to be 0.6 AE 0.2 nM (Supplementary Table 1 ). This result was comparable with the data of a previous study, in which EPO was shown to bind to neuronal cells with nanomolar affinity (Leist et al., 2004) .
Epotris induces neurite outgrowth
Because EPO can act as a neurotrophic factor (Konishi et al., 1993) , we next investigated whether Epotris could induce neurite outgrowth in primary rat neurons, previously used as an experimental model to test the neurotrophic effects of EPO (Siren et al., 2001) . Cerebellar granule neurons were stimulated with Epotris (monomer, dimer or tetramer) for 24 h ( Fig. 2A and B) . Tetrameric Epotris was the most potent inducer of neurite outgrowth, with an optimal concentration of 0.3 mM, whereas the dimeric and monomeric forms had $10-and $400-fold lower potency, respectively (Fig. 2B) . The neuritogenic effect of tetrameric Epotris was sequence-specific. A control peptide with the reverse sequence had no effect on neurite outgrowth ( Supplementary Fig. 5A ). Similarly, the Epotris tetramer induced neurite outgrowth from hippocampal neurons, with an optimal concentration of 0.3 mM (Supplementary Fig. 5B ).
The neuritogenic effect of EPO on cerebellar granule neurons was also evaluated and found to be dependent on the culture conditions. EPO induced neurite outgrowth from cerebellar granule neurons only when grown in co-culture with fibroblasts, but not on uncoated slides. Therefore, to compare the neurotrophic effects of EPO to Epotris, cerebellar granule neurons were plated on top of L-cells and stimulated with either EPO or Epotris. Both compounds induced neurite outgrowth at a broad range of concentrations (Fig. 2C) . However, the potency of Epotris was about 10 3 -fold lower than that of EPO (effective concentrations 0.1-1 mM and 0.01-50 nM, respectively).
Structural requirements for Epotris-induced neurite outgrowth
To identify which amino-acid residues are important for Epotris-induced neurite outgrowth, a library of C-and N-terminally truncated peptide derivates was tested. All truncated peptides were significantly less neuritogenic compared with the full-length Epotris peptide (Fig. 3A) . However, treatment of cerebellar granule neuron cultures with Epotris truncated from the N-terminus resulted in only a minor reduction of neurite outgrowth, whereas truncation of Epotris from the C-terminus strongly decreased or abrogated the neuritogenic effect of the peptide. Thus, the C-terminus, but not the N-terminus, of Epotris appeared to be indispensable for the ability of the peptide to induce neurite outgrowth. We termed this minimal neuritogenically active sequence (100SGLRSLTTLLRA111) Epotris-N8. We also found that Epotris-N8 promoted neurite outgrowth from neurons co-cultured with fibroblasts with the same efficiency as Epotris (Supplementary Fig. 5D ).
To identify individual amino-acid residues important for the neuritogenic activity of Epotris, a library of Epotris-N8-derived peptides was tested with single amino acids substituted for alanine. Arg110 of Epotris-N8 was crucial for the neuritogenic effect of the peptide, and substitution of Leu105, Leu109 and Thr106 inhibited the neuritogenic effect by 63, 60 and 34%, respectively (Fig. 3B) . These four amino acids in Epotris were also found to be important for the binding to EPO receptor, determined by surface plasmon resonance ( Supplementary  Fig. 4E ). 
The neuritogenic effect of Epotris is mediated by EPO receptor
EPO receptor is expressed in rodent neurons, including cerebellar granule neurons (Morishita et al., 1997; Kawakami et al., 2001 ), and we therefore investigated whether the neuritogenic effect of Epotris is mediated by EPO receptor. Knock-down of EPO receptor abrogated both EPO-and Epotris-induced neurite outgrowth in hippocampal neurons, whereas transfection with the control short-hairpin RNA had no effect (Fig. 4A) . Similar results were obtained when neurons were grown on poly-L-lysine-coated slides instead of on L-cell monolayer (Supplementary Fig. 5C ).
To study the involvement of EPO receptor in Epotris-induced neurite outgrowth further, cerebellar granule neurons were stimulated with Epotris in the presence of either control IgG or anti-EPO receptor IgG, targeting the extracellular part of the receptor (Fig. 4B) . Anti-EPO receptor, but not control IgG, dosedependently inhibited Epotris-induced neurite outgrowth. Altogether, these findings suggest that the neuritogenic effect of Epotris is mediated by neuronal EPO receptor.
EPO-induced intracellular signalling is known to involve the Jak2-Stat5 pathway (Siren et al., 2009) . Jak2 is a tyrosine kinase associated with EPO receptor, and Jak2 activation is essential for signal transduction via EPO receptor (Kawakami et al., 2001) . We therefore tested whether the neuritogenic activity of Epotris depended on Jak2 using a specific pharmacological inhibitor, AG490. AG490 dose-dependently reduced Epotrisinduced neurite outgrowth from cerebellar granule neurons, whereas neurite extension induced by an EPO-unrelated peptide, EmtinB (Ambjorn et al., 2008) , remained unaffected (Fig. 4C) .
Downstream from Jak2, Stat5 was demonstrated to be essential for EPO-induced neurotrophic activity (Byts et al., 2008) . Accordingly, Epotris applied at a concentration that induces a maximal neuritogenic response from cerebellar granule neurons (0.3 mM) increased Stat5 phosphorylation, although this effect was less pronounced than that of EPO (Fig. 4D) . A trend toward increased Stat5 phosphorylation in response to 1 mM and 3 mM Epotris was also observed, but this effect did not reach statistical significance. Altogether, these results suggest that the neurotrophic effect of Epotris is mediated by EPO receptor and the downstream Jak2-Stat5 signalling pathway.
Epotris promotes neuronal survival in vitro
EPO is neuroprotective in several in vitro models (reviewed in van der Kooij et al., 2008) . To test whether Epotris promotes cell survival, we employed two in vitro models of neuronal injury. First, cerebellar granule neuron death was induced by potassium withdrawal (D'Mello et al., 1993; Neiiendam et al., 2004) . Neuronal death could be prevented by treatment with the insulin-like growth factor-1 and partially prevented with EPO (0.13 nM, Fig. 5A ). Epotris (0.1-10 mM) also protected cells from apoptosis in this model (assessed by Hoechst staining; Fig. 5B ). These results were confirmed using another apoptosis marker, propidium iodide ( Supplementary Fig. 5E ). In a second model, death of hippocampal neurons was induced by a glutamate receptor agonist, kainic acid (300 mM). Treatment with both EPO (3 nM) and various doses of Epotris (0.001-3 mM) protected hippocampal neurons from cell death (Fig. 5C and D) . Moreover, the pro-survival effect of Epotris in this model was EPO receptor-dependent because it was abolished by anti-EPO receptor IgG (Fig. 5E ), whereas the increase in survival induced by the unrelated neuroprotective peptide Emtin B (Sonn et al., 2010) remained unaffected (Fig. 5E) . Altogether, these data suggest that Epotris exerts neuroprotection in vitro, possibly acting via EPO receptor. The potency of Epotris to increase neuronal survival is about 10 3 -fold lower than that of EPO.
Epotris crosses the blood-brain barrier
EPO can cross the blood-brain barrier after systemic administration (Brines et al., 2000; Ehrenreich et al., 2004; Xenocostas et al., 2005) . We investigated whether Epotris also penetrates the bloodbrain barrier in rats (model previously described by Ehrenreich et al., 2004) . The study was performed using biotinylated Epotris, which bound EPO receptor with an apparent affinity similar to that of non-biotinylated Epotris (Supplementary Fig. 4C ) and induced neurite outgrowth in an EPO receptor-dependent manner Cerebellar granule neurons were differentiated for 7 days in vitro in high-potassium medium (40 mM KCl) before challenge with low-potassium medium (5 mM KCl) supplemented with either (A) insulin-like growth factor 1 (IGF-1) (6.6 nM), EPO (1.3 nM) or (B) tetrameric Epotris (0.1, 0.3, 1, 3, 9 mM) for 48 h. Results from six to nine independent experiments are expressed as mean AE SEM. Asterisk indicates compared with unstimulated control (low potassium, Ctl; set as 100%). (C, D) EPO and Epotris treatment protects hippocampal neurons against kainic acid (KA)-induced excitotoxicity in vitro. Hippocampal neurons (7 days in vitro) were treated for 24 h with kainic acid (300 mM) alone or in the presence of (C) EPO (3 nM) or (D) tetrameric Epotris. Results from four to six independent experiments are expressed as mean AE SEM. Asterisk indicates compared with unstimulated control (kainic acid alone, Ctl). (E) Epotris (0.3 mM)-induced, but not EmtinB (1.5 mM)-induced neuronal survival in the kainic acid excitotoxicity model is inhibited by anti-EPO receptor IgG (0.7, 1.3 and 2.7 mg/ml). Asterisk indicates compared with Epotris-induced survival in the absence of antibodies (set as 100%). (KA+, KAÀ), neuronal survival in the untreated cultures (KAÀ) or cultures treated with kainic acid in the absence of peptides (KA+).
with the same efficiency as Epotris (Supplementary Fig. 5C ). Biotin-Epotris appeared in plasma 15 min after subcutaneous administration and remained detectable up to 24 h (Fig. 6) . The plasma concentration of peptide peaked 2 h after administration, and at this time-point Epotris was also present in CSF (Fig. 6,  inset) . Interestingly, both the reversed and scrambled versions of Epotris were also detected in CSF 2 h after subcutaneous injection (10 mg/kg, Fig. 6, inset) , suggesting that systemically administered Epotris sequence-independently crosses the bloodbrain barrier.
Epotris attenuates seizures and decreases mortality in a mouse model of kainic acid-induced brain injury EPO has previously been shown to increase the latency and reduce the severity of kainic acid-induced seizures (Brines et al., 2000) . We therefore investigated whether Epotris treatment could also delay or attenuate seizures induced by a single intraperitoneal injection of 30 or 20 mg/kg kainic acid. Mice receiving 30 mg/kg kainic acid and treated with Epotris or EPO displayed a significant delay in seizure onset (Fig. 7A) . The latency increased from 3 min in the kainic acid/vehicle-treated group to 6 min in the kainic acid/ Epotris-treated group and to 5 min in the kainic acid/EPO-treated group. Moreover, Epotris-treated mice had a 3-fold higher survival rate and significantly less severe convulsions following kainic acid injection compared with vehicle ( Fig. 7B and C, respectively) .
Kainic acid applied at a dose of 20 mg/kg induced mild seizures with no mortality. Treatment with either Epotris or EPO did not affect the latency of seizure onset at this kainic acid dose (data not shown). However, the frequency of high-grade seizures had a clear tendency toward a decrease in the Epotris-treated group [4.3 AE 1.1 in the kainic acid/Epotris-treated group (n = 13) versus 8.4 AE 1.8 in the kainic acid/vehicle-treated group (n = 10), P = 0.052].
Epotris decreases kainic acid-induced neurodegeneration
Systemic administration of kainic acid is known to cause neurodegeneration in susceptible brain regions, such as the hippocampus, thalamus, cortex and amygdala (Benkovic et al., 2006) . Treatment with EPO has been previously reported to prevent neuronal death following pilocarpine-induced status epilepticus (Nadam et al., 2007; Chu et al., 2008) . Because Epotris treatment attenuated seizures in vivo and protected hippocampal neurons from kainic acid-induced toxicity in vitro, we next investigated whether Epotris also diminished kainic acid-induced neurodegeneration in vivo. Indeed, animals treated with Epotris or EPO had significantly less neuronal damage in the CA1 and CA3 regions of the hippocampus and cortex after kainic acid administration (Fig. 8 , assessed by Fluoro-Jade staining). Similar results were obtained in a separate experiment using haematoxylin-eosin staining ( Supplementary Fig. 6 ). In this setup, there was a slight difference in the neuroprotective effect of EPO, which reached significance in CA1 and CA3, but not in the cortex, probably reflecting difference in the detection method. Altogether, the histological data confirmed that Epotris rescues cells from kainic acid-induced toxicity.
Epotris is not erythropoietic in vivo
Because EPO is a well-known haematopoietic factor (Chen et al., 2006) , we next investigated whether Epotris also possesses haematopoietic properties in vitro and in vivo. We first tested whether Epotris affects proliferation of the human leukaemia cell line TF1. No effect of the peptide was observed at concentrations up to 10-fold higher than its optimal neuroprotective concentration (1-2.3 mM), but when applied at 5 mM, Epotris increased TF1 cell proliferation ( Supplementary Fig. 5F ). Administration of Epotris (10, 20 or 40 mg/kg, subcutaneous) to C57Bl/6J mice twice weekly for 5 weeks affected neither the level of haemoglobin nor the concentration of red blood cells (Fig. 9A and B, respectively) during the injection period and after a recovery period of 1 additional week. Epotris also had no augmenting effect on haematocrit (data not shown). In contrast, EPO-treated animals exhibited a significant increase in both haemoglobin and red blood cells. Similar results were obtained in a separate haematopoietic study performed in BALB/c mice employing 10 mg/kg of Epotris ( Supplementary Fig. 7) . Thus, although Epotris increased proliferation of the leukaemia cell line in vitro when applied at a high concentration, it did not stimulate haematopoiesis after long-term systemic administration. To test whether the lack of haematopoietic activity of Epotris in vivo could be attributed to antibody formation in response to the peptide (an effect previously described for EPO; Siren et al., 2009) , the plasma samples taken at Week 6 were analysed by enzyme-linked immunosorbent assay for the presence of anti-Epotris antibodies. No difference between the vehicle-and Epotris-treated groups was found (data not shown).
Discussion
In this study, we show that a 20-meric EPO-derived peptide, Epotris, has neuroprotective and neurotrophic effects in several in vitro models. We also demonstrate that systemically Quantitative analysis of histopathology in the corresponding subfields expressed as mean of degenerating neurons AE SEM. The control (n = 6) shows the absence of neurodegeneration in the CA1 and CA3 subfields and cortex. Kainic acid administration significantly increased the number of degenerating neurons (KA + vehicle, n = 6) in all three areas. Treatment with EPO or Epotris (KA + EPO, KA + Epotris, n = 6 in both groups) markedly reduced neuropathological changes in the CA1 and CA3 subfields and cortex. * indicates compared with KA + vehicle-treated group. Scale bar = 50 mm.
administered Epotris penetrates the blood-brain barrier and has both anti-epileptic and neuroprotective effects in an animal model of kainic acid-induced neurotoxicity. Moreover, multiple doses of Epotris do not stimulate haematopoiesis in vivo.
Extensive evidence suggests that EPO is involved in neuroprotection, probably acting through the neuronal EPO receptor Ruscher et al., 2002; Yu et al., 2002) . EPO is up-regulated in neurons in response to hypoxia and metabolic stress in vitro and in vivo (Sadamoto et al., 1998; Sanchez et al., 2009a) . EPO was originally thought to exert its biological effects through the EPO receptor homodimer (Maiese et al., 2005) . This was unambiguously demonstrated for the haematopoietic function of EPO (Brines and Cerami 2005) . Later, the neuroprotective activity of recombinant human EPO and some EPO-derivates was suggested to be mediated by a heterocomplex of EPO receptor and CD131 (bc) (Brines et al., , 2008 . However, recent data indicate that EPO exerts neuroprotection through EPO receptor independently of bc (Nadam et al., 2007) . Moreover, bc was not detected in neuronal cells that respond to EPO (Um et al., 2007; Sanchez et al., 2009b) . Thus, EPO may exert neuroprotection through the EPO receptor homodimer, the EPO receptor/bc heteroreceptor, or another yet unidentified receptor.
Our results show that Epotris can bind to and act via EPO receptor. Interestingly, although we found sequence-specific binding of Epotris to EPO receptor (K D $4.5 nM), we could not detect any interaction between Epotris (which is derived from helix C) and the immobilized CD131 receptor (Supplementary Fig. 4B ). These data support a recent hypothesis by Brines et al. (2008) , in which helix B (but not helix C) was suggested to be responsible for EPO binding to CD131 (Brines et al., 2008) .
According to the crystal structure of the EPO-EPO receptor complex, the intermolecular contact area of the secondary binding site is 687 Å 2 (Syed et al., 1998) . The Epotris sequence covers only 374 Å 2 of this area, suggesting that the peptide may have binding properties and biological activity different from those of EPO.
Indeed, point-directed mutagenesis of EPO has revealed a subset of residues (Arg103, Ser104, Leu105, Leu108 and Arg110) in Site 2 responsible for the proliferation effect of EPO (Wen et al., 1994; Matthews et al., 1996; Elliott et al., 1997) . In this study, residues Leu105 and Arg110, but not Arg103, Ser104, or Leu108, were crucial for the neuritogenic effect of Epotris. The difference in the effects of mutations in EPO and Epotris suggests that EPO receptor, upon binding Epotris, is likely to adopt an orientation that is different from its 'native' conformation within the EPO:EPO receptor-2 complex. The binding affinity of EPO to EPO receptor is $10-fold higher than that of the peptide. In addition, the association and dissociation rate constants of the peptide and EPO are markedly different. The peptide has $50 times slower association and $15 times slower dissociation compared to EPO (Supplementary Table 1 ). This difference in the kinetics of the ligand-receptor interactions probably results in the lower potency of Epotris than EPO to induce biological response. These data also suggest that the peptide may act as a partial agonist of the EPO receptor. In line with this, the binding determinants of another EPO receptor binding peptide, erythropoietin mimetic peptide 1 (an EPOunrelated peptide identified by phage display), were shown to be different from those of EPO (Middleton et al., 1999) . Moreover, the erythropoietin mimetic peptide 1 binds only four of the six receptor loops occupied by the native cytokine in the EPO/EPO receptor complex (Livnah et al., 1996) , supporting the hypothesis that EPO and its peptide mimetics activate EPO receptor through different permissive inter-receptor geometries (Kaushansky, 2001) .
In our experiments, tetrameric Epotris acquired a conformation similar to -helix C of EPO. We suggest that in a tetrameric peptide, which forms -helices in solution ( Supplementary Fig.  3 ), the four chains are arranged such that their hydrophobic sides are packed together, leaving the hydrophilic side chains free for interactions with EPO receptor molecules. The dimeric, and especially monomeric, form of the peptide probably is more Figure 9 Epotris is not erythropoietic in vivo. Mice were injected twice per week with Epotris (10, 20, or 40 mg/kg, n = 10), EPO (10 mg/kg, n = 8) or vehicle (Veh, n = 8) for 5 weeks. Injection days are marked by arrowheads. Haemoglobin (Hb) levels (A) and red blood cell (RBC) counts (B) were measured once per week for 6 weeks. The data were normalized to Vehicle (set to 100%). Asterisk indicates compared with untreated mice at Day 0. s.c. = subcutaneous.
Novel EPO receptor agonist Brain 2010: 133; 2281-2294 | 2291 disordered and therefore less efficient than the tetrameric form with regard to both EPO receptor binding and induction of neurite outgrowth (Fig. 2B) . Indeed, we could not detect binding of monomeric Epotris to EPO receptor ( Supplementary Fig. 4C ), and the monomer only induced neurite outgrowth at a very high concentration (116 mM), suggesting that its neuritogenic effect could be non-specific.
Although the existence of additional co-receptors for EPO has been suggested , we observed complete inhibition of EPO-and Epotris-induced neurite outgrowth when EPO receptor was knocked down. These results are consistent with a previous report, in which EPO exerted neurotrophic effects in retinal ganglion cells through EPO receptor (Bocker-Meffert et al., 2002) . The pro-survival effect of Epotris appeared to be also dependent on EPO receptor because it was inhibited by anti-EPO receptor.
In our experiments, both EPO and Epotris induced phosphorylation of the EPO receptor effector Stat5, which was recently shown to be essential for the neurotrophic activity of EPO (Byts et al., 2008) . Furthermore, the Jak2/Stat5 pathway inhibitor AG490 significantly attenuated neurite outgrowth induced by Epotris, but not by the unrelated EmtinB peptide. These findings strongly support the role of the Jak2/Stat5 cascade in Epotris-induced neurite outgrowth.
The neuroprotective activity of EPO has been well documented in various in vitro models (Morishita et al., 1997; Siren et al., 2001) . Here, Epotris was identified as a neuroprotective compound in vitro, rescuing neurons from kainic acid-and potassium deprivation-induced cell death. Moreover, Epotris delayed and attenuated seizures, and decreased neurodegeneration in an animal model of kainic acid-induced excitotoxicity, which is widely used as a model of human temporal lobe epilepsy (Ben-Ari, 1985) . Interestingly, EPO treatment has also been shown to ameliorate seizures, reverse the development of status epilepticus, and protect hippocampal neurons in several models of epilepsy (Brines et al., 2000; Nadam et al., 2007; Chu et al., 2008) . Thus, Epotris mimicked the beneficial effects of EPO not only in vitro, but also in vivo, rendering the peptide a promising neuroprotective agent. However, the peptide did not mimic the haematopoietic activity of EPO: Epotris had low potency in vitro to induce proliferation of leukaemia cells and did not affect haematopoiesis in vivo.
Although further experiments are needed to reveal the mechanisms underlying Epotris-induced neuronal protection, our results strongly suggest that Epotris may recruit the same neuroprotective signalling cascades as EPO. Together with the peptide's ability to cross the blood-brain barrier and the absence of haematopoietic activity in vivo, this makes Epotris an attractive drug candidate for the treatment of neurodegenerative disorders.
